Monica Lominchar, MD
Internal Medicine · Charleston, SCNPI 1770532764
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $124 and has fallen 89.0% since, to $14 in 2025. That places this record below the midpoint for internal medicine clinicians in SC, where the typical reported total is $298.
Across 16 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$94
- Insulet Corporation$75
- Novo Nordisk$69
- Lilly USA, LLC$68
- Johnson & Johnson$45
- Otsuka America Pharmaceutical, Inc.$25
- plus $29 from 2 others
Across 2 payments — averaging $4411.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vanda Pharmaceuticals Inc.$9K
What the payments were for
- Food & beverage$39297%
- Education$123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $94 |
| Insulet Corporation | 1 | $75 |
| Novo Nordisk | 4 | $69 |
| Lilly USA, LLC | 4 | $68 |
| Johnson & Johnson | 1 | $45 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Intra-sana Laboratories | 1 | $14 |
How this compares
$404 in reported general payments places this provider in the 50th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 72 | $117,209 |
| MounjaroTirzepatide | 30 | $35,727 |
| JanuviaSitagliptin Phosphate | 11 | $13,371 |
| AdderallDextroamphetamine/Amphetamine | 11 | $6,918 |
| Spiriva HandihalerTiotropium Bromide | 11 | $6,695 |
| Clorazepate Dipotassium | 11 | $1,278 |
| Bupropion XlBupropion Hcl | 29 | $1,226 |
| Atorvastatin Calcium | 71 | $1,011 |
| Levothyroxine Sodium | 67 | $1,001 |
| Armour ThyroidThyroid,pork | 11 | $839 |
| Fluticasone Propionate | 47 | $776 |
| Valsartan | 15 | $699 |
| Amlodipine Besylate | 97 | $634 |
| Montelukast Sodium | 36 | $592 |
| Rosuvastatin Calcium | 42 | $557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $69 | $117,20972 claims |
| Lilly USA, LLCMounjaro | $68 | $35,72730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Charleston
- Jan BasileCharleston$278K
- John CleekCharleston$136K
- Leonard AlsfeldCharleston$91K
- Brett TomashitisCharleston$36K
- Scott SandsCharleston$25K
- Laura KinneyCharleston$20K
- Andrew SchreinerCharleston$15K
- Hardik PatelCharleston$15K
- Mithunan MaheswaranathanCharleston$14K
- Frances HughesCharleston$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.